Allergan, Inc.
U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Parsippany
New Jersey
07054
United States
Tel: 1 (862) 261-7000
Website: http://www.allergan.com/
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
YEAR FOUNDED:
1948
LEADERSHIP:
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1059 articles with Allergan, Inc.
-
AbbVie to Acquire Allergan in Transformative Move for Both Companies
6/25/2019
Provides immediate scale and profitability to AbbVie's growth platform, excluding Humira, significantly expanding and diversifying its revenue base with new therapeutic areas, including Allergan's leading medical aesthetics business
-
The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company's long-term reliance on its cash cow, Humira.
-
Allergan Receives FDA Clearance For CoolTone™ Device
6/24/2019
Magnetic muscle stimulation technology to strengthen, tone and firm muscles
-
Clinical Catch-Up for June 17-21
6/24/2019
Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories. -
FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
6/21/2019
BOTOX® is the First Neurotoxin Treatment Approved to Treat Pediatric Patients, 2 to 17 Years of Age, with Upper Limb Spasticity
-
Allergan announced that the U.S. Food and Drug Administration has approved its wrinkle treatment Botox for children with upper limb spasticity. The news comes just days after rumors that the company may break up.
-
The drug showed a statistically significant and clinically meaningful improvement in overall abdominal symptoms compared to placebo for all primary and secondary endpoints.
-
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
6/18/2019
Phase IIIb study met all primary and secondary endpoints with statistical significance and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C
-
FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
6/13/2019
Amgen and Allergan plc announced that the U.S. Food and Drug Administration has approved KANJINTI™ for all approved indications of the reference product, Herceptin®: for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
-
Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D
6/3/2019
Top-line data from Phase II trial expected in second half 2020
-
Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
5/28/2019
New Indication Makes VRAYLAR First and Only Dopamine and Serotonin Partial Agonist to Treat the Full Spectrum of Bipolar I Symptoms in Manic, Mixed, and Depressive Episodes
-
There are approximately 11 million adults in the U.S. living with bipolar disorder, a condition that causes extreme shifts in mood, energy and activity levels.
-
Allergan Announces Updated Presentation Time at the Bernstein Strategic Decisions Conference
5/24/2019
Allergan plc announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35th Annual Strategic Decisions Conference in New York, NY.
-
Allergan to Present at the Jefferies 2019 Healthcare Conference
5/23/2019
Allergan plc announced that Chief Commercial Officer William Meury will participate in a fireside chat at the Jefferies 2019 Healthcare Conference in New York, NY.
-
Allergan Expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
5/17/2019
Allergan plc (NYSE: AGN) today announced the expansion of the PLEDGE program with a fifth study now evaluating relamorelin, an investigational, ghrelin agonist being studied for the treatment of diabetic gastroparesis (DG).
-
Allergan to Present at the Bernstein Strategic Decisions Conference
5/16/2019
Allergan plc announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35th Annual Strategic Decisions Conference in New York, NY.
-
Allergan to Present VRAYLAR® (cariprazine) Data at the American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment to Mental Health
5/15/2019
Allergan plc announced it will showcase data during the upcoming American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18 – May 22, 2019.
-
PatientFi® Announces Study Partnership with Allergan
5/15/2019
Commercial Study Will Measure Impact of Increasing Access and Affordability of Aesthetic Procedures
-
Allergan to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
5/9/2019
Allergan plc announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, Nevada.
-
With key investors upset about Allergan's share price, Saunders pointed to five potential drugs on the market within the next 18 months.